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istration of patients, the management of adverse events and the cost of medica-
tion. A 3.5% discount rate was used for the case of all outcomes. Monte Carlo
simulation was employed to construct the 95% uncertainty intervals (UI) and to
compute cost-effectiveness acceptability curve. RESULTS: The mean total QALYs
estimate in the Len/Dex armwas 2.95 (95%UI: 2.75-3.14) and 2.20 (95%UI: 1.99-2.40)
in the case of bortezomib, an incremental gain of 0.75 (95%UI: 0.47-1.02) QALYs. The
mean total therapy cost was estimated at €76,782 (95%UI: 75,689-€77,927) and
46.380€ (95%UI: 45,719€-47,000€) for Len/Dex and Bortezomib, respectively. For both
comparators, total therapy cost ismainly attributed tomedication. The cost per life
year gained was estimated at €35,081 (95%UI: €19,357-€73,180) and the cost per
QALY gained at €42,012 (95%UI: 29,445-64,217). The probability for Len/Dex to be a
cost-effective therapy option at a threshold three times the per capital income
(€60,000 per QALY), was higher than 95%. Results remained constant under several
one-way sensitivity analyses.CONCLUSIONS:Therefore therapywith combination
of Len/Dex appears to be a cost-effective choice compared with Bortezomib alone
for multiple myeloma patients in Greece.
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OBJECTIVES: Currently in Brazil, acromegaly patients who fail having biochemical
control with somatostatine analogues face an unmet need. This research aims to
assess the economic impact of introducing pegvisomant to treat patients under the
public health care systemperspective.METHODS:An economicmodel considering
patients treatedwith Pegvisomant (PtwP) andpatientswithout biochemical control
(PWoC) was developed by using the available literature and Brazilian public data-
bases to evaluate the frequency of the following outcomes: Life years gained (LY),
quality adjusted life years gained (QALYs), cases of diabetes mellitus (DM), high
blood pressure (HBP), myocardial infarctions (MI), joint replacement surgeries (JR)
and number of life years without DM, HBP or MI (YWoDHM). The model was com-
posed by a decision tree portion to evaluate “JR” or “no JR” heath states, fromwhich
one-year Markov cycles were initiated considering the following health states: No
morbidity; DM; HBP; MI; HBPDM; DMMI; HBPMI; HBPDMMI; death. Proba-
bility inputs would either follow general population data to estimate biochemical
control or active acromegaly data to depict treatment failure. The time horizonwas
defined as 37 years, lifetime for PWoC since diagnose. Probabilistic sensitivity anal-
ysis was performed byMonte Carlo simulation using 10.000 iterations. 5% discount
rates were applied to costs and benefits. Values were represented in 2010 USD.
RESULTS: The values for PtwP versus PWoC were: 152.382 versus 143.935 for LY;
116.201 versus 87.227 for QALYs; 2.738 versus 6.141 for DM cases; 5.247 versus 7.244
for HBP cases; 753 versus 778 for MI cases; 67 versus 327 for JR cases and 219.319
versus149.896 for YWoDHM. ICERs for LY and QALYs were USD305.078,60 and
USD89.068,00, respectively. CONCLUSIONS: Pegvisomant has an important role in
reducing premature deaths and morbidities such as DM, HBP, JR and MI to the
PWoC under the public heath perspective in Brazil. Real world data is necessary to
identify underlying costs for the studied population.
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OBJECTIVES: CML is a malignant orphan disease of the blood and bone marrow.
Imatinib 400mg (up to 800mg with inadequate responses) daily is currently recom-
mended for treatment of newly diagnosed patients or after failure with interfer-
on-. Dasatinib 100 mg daily has been shown to offer significant clinical efficacy in
patients failing imatinib. Its cost-effectiveness compared to imatinib 600/800 mg
has not been assessed in this patient group. METHODS: A partitioned survival/
costingmodel was developed to estimate the lifetime costs and benefits associated
with dasatinib and imatinib from a UK health service perspective using a lifetime
horizon and monthly cycles. Prognosis was assigned for dasatinib and imatinib
patients to each of five initial best clinical response categories at 12 months. Re-
sponse category specific survival was based on long-term data from IRIS clinical
trial and response rates froma phase III randomized study. Utility and resource use
data were taken from recent UK based studies and all unit/drug costs were taken
from appropriate national databases and discounted at 3.5%per annum. Probabi-
listic and deterministic sensitivity analyses were conducted to estimate the confi-
dence around the results. Outcomes are reported via incremental cost-effective-
ness ratios (ICERs); benefit is expressed as quality adjusted life years (QALYs).
RESULTS: Compared to imatinib, dasatinib offered an additional 3.53 QALYs but
incurred £90,800 of additional costs. The ICER was therefore £25,700/QALY gained.
At a threshold of £30,000/QALY gained, dasatinib had a 98.1% probability of being
cost-effective. Deterministic analysis showed that the model was sensitive to
changes in 12 month response probabilities and drug costs. The model was robust
to changes in adverse event rates/ costs, and to utility estimates. CONCLUSIONS:
Dasatinib has been shown to be clinically superior to imatinib in CML patients who
have failed imatinib treatment and is a cost-effective alternative to imatinib dose
escalation in this patient group.
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OBJECTIVES: CML is a malignant blood disease. Imatinib 400mg daily is currently
recommended in newly diagnosed CML patients. Compared to imatinib, dasatinib
100mg daily has been shown to offer significant improvements in clinical efficacy
but its cost-effectiveness compared to imatinib has not been assessed in this pa-
tient group. METHODS: A partitioned survival/costing model was developed to
estimate the lifetime costs and benefits associated with dasatinib and imatinib for
a UK health service perspective using a lifetime horizon and monthly cycles. Indi-
viduals could switch from first to second line treatment at 3, 12 or 18 months for
reasons of inadequate clinical response and monthly for all other reasons. Re-
sponse category specific survival was based on long-term data from IRIS clinical
trial and response rates from a recent network-meta-analysis. Utility and resource
use datawere taken fromUK based studies and all unit/drug costs were taken from
national databases and discounted at 3.5% per annum. Probabilistic and determin-
istic sensitivity analyses were conducted to estimate the confidence around the
results. Outcomes are reported via incremental cost-effectiveness ratios (ICERs),
benefit is expressed as quality adjusted life years (QALYs). RESULTS: Compared to
imatinib, dasatinib offered an additional 0.71 QALYs (95% CI -0.15, 1.68) but in-
curred £17,646 of additional costs (95%CI -£24,259, £57,947). The ICERwas therefore
£24,922/QALY gained. At a threshold of £30,000/QALY gained, dasatinib had a 62.6%
probability of being cost-effective. Deterministic analysis showed that the model
was sensitive to changes in the 12-month response probabilities and drug costs.
When trial observed dose intensities were used, the ICER was £13,400/QALY
gained. The model was robust to changes in adverse event rates/ costs, and utility
estimates. CONCLUSIONS: Dasatinib has been shown to be clinically superior to
imatinib in newly diagnosed CML patients and is a cost-effective alternative to
imatinib in this patient group.
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OBJECTIVES: This study reports dosing and refill compliance observed in goli-
mumab (GLM)-treated ankylosing spondylitis (AS) patients.METHODS: This retro-
spective analysis assessed GLM use in adult AS patients with2 GLM prescriptions
between April 24, 2009 and December 31, 2010;  1 AS diagnosis during the study
period; continuous activity in the Source® LX database (6 months before; 6
months after the index GLM prescription); and a 28-31 day GLM supply. Refill com-
pliance was defined as 1 week of the expected 28-31 day (d) interval. The percent
of compliant GLM refill intervals and the percent of patients demonstrating refill
compliance at the 6th GLM dose were assessed. Data were summarized with de-
scriptive statistics. RESULTS: A total of 99 AS patients and 559 GLM refill intervals
were studied. The sample was 53% male; mean age of 44 years with 72% bio-
experienced. A 50 mg GLM dose occurred in 99% of all fills. The mean  SD refill
interval for the populationwas 35.121.0 dwith amedian of 30 d. The refill interval
of bio-experienced patients (34.818.7 d; median 30 d) was similar to bio-naïve
patients (35.825.8 d; median 31 d). Refill compliance was observed in 79% of all
intervals. Refill compliance at the 6th GLM dose was achieved by 83% of patients
overall.CONCLUSIONS: In this retrospective administrative claims analysis, 99% of
GLM doses were 50 mg with approximately once monthly refill intervals. Overall
refill compliance was observed in nearly 80% of all GLM refills and in greater than
80% of AS patients at the sixth GLM dose. Median refill interval and refill compli-
ance appeared similar in bio-experienced and bio-naïve subgroups. Further study
of these trends using additional data sources are desired to substantiate these
preliminary findings.
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OBJECTIVES: To understand how patients perceived the relevance and ease of
understanding of the questions included in SAT questionnaire to reflect key pa-
tient-reported outcomes of NP treatments and to provide recommendations mod-
ifications based on patient clinician interviews.METHODS: Semi-structured inter-
views were conducted with clinicians and NP patients to inform on treatment
attributes and pain impacts. Patients were debriefed on the SAT, a 5-item scale
evaluating pain, activity level, quality of life (QL) and satisfaction with treatment
(recommend treatment and undergo treatment again). SAT has a recall period
reflecting back to initiation of treatment. The qualitative analysis software AT-
LAS.ti 5.0 was used to analyze patient transcripts. Changes to SAT underwent
debriefings. RESULTS: Three NP clinicians and 44 patients (20 painful diabetic neu-
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